Limited Use Note(s) |
|
RANIBIZUMAB10mg/mL Inj Sol-Pref Syr 0.165mL Pk
| Reason For Use Code | Clinical Criteria |
|---|---|
| 655 | For the treatment of age-related macular degeneration (AMD), diabetic macular edema (DME), branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO) or choroidal neovascularization, but only for patients established on Lucentis (ranibizumab) therapy prior to July 31, 2023. |
| LU Authorization Period: 1 year |